Carregant...
Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
[(223)Ra]RaCl(2) is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [(223)Ra]RaCl(2) is excreted via the intestine into feces, and some is absorbed from the intestine...
Guardat en:
| Publicat a: | Sci Rep |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7368038/ https://ncbi.nlm.nih.gov/pubmed/32681007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-68846-x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|